{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:10:20Z","timestamp":1758474620416,"version":"3.41.2"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2016,7]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Although dopamine agonists (DA<\/jats:styled-content>s) are useful in Parkinson\u2032s disease (PD<\/jats:styled-content>), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD<\/jats:styled-content> patients are enrolled in clinical trials.<\/jats:p><\/jats:sec>Aims of the study<\/jats:title>The aims of this study were to analyze the reasons of DA<\/jats:styled-content> withdrawal (DAW<\/jats:styled-content>) in a group of PD<\/jats:styled-content> patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>A retrospective chart review of the follow\u2010up (from May, 2012 to March, 2015) of a subgroup of PD<\/jats:styled-content> patients receiving a DA<\/jats:styled-content> (n<\/jats:italic>\u00a0=\u00a068; 60.3% males, 69.3\u00a0\u00b1\u00a09.2\u00a0years old) from a cohort (n<\/jats:italic>\u00a0=\u00a0150) previously studied in detail in 2012 was used to identify predictive factors of DAW<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>The DAW<\/jats:styled-content> percentage was 18.2% (12\/66; follow\u2010up of 690.2\u00a0\u00b1\u00a0232.6\u00a0days). DAW<\/jats:styled-content> causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR<\/jats:styled-content> 1.003; 95% CI<\/jats:styled-content> 1.001\u20131.006; P<\/jats:italic>\u00a0=\u00a00.044) was an independent predictor of DAW<\/jats:styled-content> after adjustment for other explanatory variables.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The frequency of DAW<\/jats:styled-content> was low. Advanced age alone is not a contraindication to the administration of DA<\/jats:styled-content>s.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.453","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T04:09:13Z","timestamp":1462507753000},"source":"Crossref","is-referenced-by-count":8,"title":["Causes and factors related to dopamine agonist withdrawal in Parkinson\u2032s disease"],"prefix":"10.1002","volume":"6","author":[{"given":"Ester Su\u00e1rez","family":"Castro","sequence":"first","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Santos\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"de Deus Fonticoba","sequence":"additional","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Exp\u00f3sito Ru\u00edz","sequence":"additional","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia","family":"Tu\u00f1as Gesto","sequence":"additional","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes Mac\u00edas","family":"Arrib\u00ed","sequence":"additional","affiliation":[{"name":"Section\u00a0of Neurology Complejo Hospitalario Universitario de Ferrol (CHUF) Hospital A. Marcide Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.2.159"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0518-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0708-6"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265593.34438.00"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.03.003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21743"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm142"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883\u2010015\u20100267\u20107"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550230060018"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1258\/smj.2012.012121"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.06.009"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.32"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03506.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.07.005"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12305"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.03.018"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.nrl.0000215782.78763.fa"},{"key":"e_1_2_7_21_1","first-page":"CD006564","article-title":"Dopamine agonist therapy in early Parkinson\u2032s disease","author":"Stowe R. L.","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23429"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2009.07.018"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.453","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:27:52Z","timestamp":1696570072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/brb3.453"],"URL":"https:\/\/doi.org\/10.1002\/brb3.453","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"type":"print","value":"2162-3279"},{"type":"electronic","value":"2162-3279"}],"subject":[],"published":{"date-parts":[[2016,5,5]]},"article-number":"e00453"}}